Celecoxib-induced upper gastrointestinal hemorrhage and ulceration

Southern Medical Journal

Volumn 95, Issue 12, 2002, Pages 1444-1446

  Crawford, Andrew S ^a,b   White, Joseph G ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Clinic 3B   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CULTURE; BLOOD PRESSURE MONITORING; BLOOD TRANSFUSION; CARDIOVERSION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTRODUODENAL ULCER; HEART ELECTROPHYSIOLOGY; HEMORRHAGIC GASTRITIS; HUMAN; INTENSIVE CARE UNIT; MALE; OSTEOARTHRITIS; STOMACH EROSION; STREPTOCOCCUS SALIVARIUS; TREATMENT FAILURE; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

EID: 0036991947     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200295120-00019     Document Type: Article

References (16)

1. Lanza FL: A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93:2037-2046
2. Geis GS: Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 1999; 26(suppl 56):31-36
3. Singh G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105:31s-38s
4. Smith WL, Dewitt DL: Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62:167-215
5. Vane JR, Botting RM: New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44:1-10
6. Seibert K, Zhang Y, Leahy K, et al: Pharmacologic and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91:12013-120137
7. Vane JR, Mitchell JA, Appleton I, et al: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91:2046-2050
8. Simon LS, Lanza FL, Lipsky PE, et al: Preliminary study of the safety and efficacy of SC-586S5, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998; 41:1591-1602
9. Masferer JL, Zweifel BS, Manning PT, et al: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91:3228-3232
10. Simon LS, Weaver AL, Graham DY, et al: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282:1921-1928
11. Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929-1933
12. Schmaussmann A, Peskar BM, Stettler C, et al: Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123:795-804
13. Gretzer B, Ehrlich K, Maricic N, et al: Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 1998; 123:927-935
14. Mizuno H, Sakamoto C, Matsuda K, et al: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112:387-397
15. Wallace JL, Reuter BK, McKnight W, et al: Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? J Clin Gastroenterol 1998; 27(suppl 1):S28-S34
16. Wallace JL, Bak A, McKnight W, et al: Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998; 115:101-109